BioLineRx Ltd. (BLRX) AI Stock Analysis

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Hevel Modi'in, Israel, focused on developing treatments in oncology. Its core pipeline asset is Motixafortide, a peptide that has completed Phase 3 trials for autologous stem cell mobilization and Phase 2a trials for pancreatic cancer. Motixafortide is also being tested in Phase 2 trials for metastatic pancreatic adenocarcinoma, as well as Phase 1b trials for acute respiratory distress syndrome, solid tumors, and acute myeloid leukemia. Other pipeline programs include AGI-134 for solid tumors and BL-5010 for non-surgical skin lesion removal. BioLineRx collaborates with partners including MSD, MD Anderson Cancer Center, and Perrigo Company plc.

BioLineRx generated revenue of $4.8M in FY2023, which expanded to $28.9M in FY2024 with a revenue growth rate of 502.9% and a gross margin of 68.0%. In FY2025, revenue contracted by 95.9% to $1.2M, while gross margin decreased to 36.2%. The company recorded net losses of -$60.6M in FY2023, -$9.2M in FY2024, and -$1.2M in FY2025, corresponding to an operating margin of -871.8% in FY2025. Over the two-year period from FY2023 to FY2025, revenue compounded at a CAGR of -50.2%. For the trailing twelve months ended June 30, 2026, revenue stood at $1.4M, with quarterly revenue falling 3.3% year-over-year.

As of June 30, 2026, BioLineRx held $13.1M in cash and short-term investments and $7.9M in total debt, resulting in a net cash position of $5.1M. Shareholders' equity was $13.8M, total assets were $33.5M, and the current ratio was 1.20. In FY2025, operating cash flow was -$8.1M and free cash flow was -$8.2M, while capital expenditures totaled $25,200. Over the past five years, the company's share count increased by 302.0%.

BioLineRx trades at a forward P/E of 93.5x, well above the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 7.2x, compared to the peer median of 4.1x, while its EV/EBITDA stands at 1.1x versus the peer median of 12.0x. The company has an enterprise value of $7.4M and a market capitalization of $10.0M. Over the past year, the stock returned -47.4%, trailing the S&P 500 benchmark return of 16.8%, and its five-year return stands at -98.4% compared to 83.0% for the index.

BioLineRx has 1 StrongBuy rating from analysts, with 0 Buy, 0 Hold, 0 Sell, and 0 StrongSell ratings. The mean price target is $22.00, compared to the last close of $2.01, representing a target variance of 994.5%. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$3.14 on revenue of $1.6M. For the following fiscal year, 1 analyst estimates EPS of -$2.52 and revenue of $2.2M, reflecting expected revenue growth of 37.1%. BioLineRx beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 23, 2026.

This page is an AI-written research summary of BioLineRx Ltd. (BLRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BLRX income statement, BLRX balance sheet, BLRX key metrics, BLRX analyst forecast, BLRX chart. See the BLRX stock overview for the latest quote and news.